Buy Generic Fenofibrate Online

Generic Fenofibrate Information

Introduction

Fenofibrate is a lipid‑modifying agent classified within the cholesterol‑lowering medication group. It is widely used in Hong Kong to manage dyslipidaemia, particularly elevated triglycerides and low high‑density lipoprotein (HDL) cholesterol. The active compound is fenofibrate, and the drug is available both as branded products (e.g., Tricor) and as generic formulations. In addition to its primary indication for hypertriglyceridaemia, fenofibrate is employed in mixed dyslipidaemia and in the prevention of cardiovascular complications associated with abnormal lipid profiles.

What is Fenofibrate?

Fenofibrate is the generic version of Tricor, Lofibra, and other well‑known brand names, containing the same active compound fenofibrate. Our online pharmacy provides this generic alternative as a cost‑effective treatment option. It belongs to the fibrate class of drugs, which are synthetic analogues of the natural fatty acid ligand peroxisome proliferator‑activated receptor‑α (PPAR‑α). The compound was first approved by the U.S. Food and Drug Administration in 1993 and is marketed worldwide by several manufacturers, including Abbott Laboratories (now part of AbbVie) for the branded formulation.

How Fenofibrate Works

Fenofibrate activates the nuclear receptor PPAR‑α, primarily expressed in hepatic tissue, muscle, and adipose tissue. Activation of PPAR‑α leads to increased transcription of genes involved in β‑oxidation of fatty acids, reduction of apolipoprotein C‑III synthesis, and enhanced lipoprotein lipase activity. Consequently, the drug accelerates the catabolism of triglyceride‑rich very‑low‑density lipoprotein (VLDL) particles, lowers serum triglyceride concentrations, and modestly raises HDL‑cholesterol levels. The onset of lipid‑lowering effects typically occurs within 2 weeks, with maximal efficacy reached after about 4–6 weeks of consistent dosing. Fenofibrate is eliminated mainly via hepatic metabolism and renal excretion; the half‑life ranges from 20 hours (immediate‑release) to 50 hours (microsphere formulations).

Conditions Treated with Fenofibrate

• Primary hypertriglyceridaemia – Elevated fasting triglycerides (> 150 mg/dL) are common in Hong Kong, driven by dietary patterns high in refined carbohydrates and metabolic syndrome. Fenofibrate reduces triglycerides by 30‑50 % and helps meet guideline targets (e.g., 202 Hong Kong Society of Lipidology recommendations).
• Mixed dyslipidaemia – Patients with concurrent high triglycerides and low HDL‑cholesterol benefit from fenofibrate’s dual action, improving the atherogenic lipid profile.
• Familial combined hyperlipidaemia – Genetic predisposition to elevated VLDL particles can be moderated with fibrate therapy.
• Secondary dyslipidaemia – Conditions such as type 2 diabetes mellitus, obesity, and metabolic syndrome often present with triglyceride elevation; fenofibrate is an adjunct to lifestyle modification and glucose‑lowering agents.

Clinical trials, including the FIELD and ACCORD Lipid studies, demonstrated that fenofibrate reduces cardiovascular events in subpopulations with high triglycerides and low HDL‑cholesterol, supporting its use in primary and secondary prevention strategies.

Who is Fenofibrate For?

• Adults (≥ 18 years) with documented fasting triglyceride levels ≥ 200 mg/dL, especially when lifestyle measures alone are insufficient.
• Patients with mixed dyslipidaemia who exhibit a triglyceride‑dominant pattern and a low HDL‑cholesterol (< 40 mg/dL for men, < 50 mg/dL for women).
• Individuals with type 2 diabetes mellitus who have atherogenic dyslipidaemia despite optimal glycaemic control.
• Patients at elevated cardiovascular risk (e.g., established coronary artery disease) whose lipid profile meets the above criteria.

Fenofibrate is not appropriate for patients with severe hepatic impairment (Child‑Pugh class C), active gallbladder disease, or a known hypersensitivity to the drug or any of its excipients. Caution is advised in moderate renal impairment (creatinine clearance 30–50 mL/min) and in patients taking statins, as co‑administration increases the risk of myopathy.

Risks, Side Effects, and Interactions

Common

• Gastro‑intestinal upset (nausea, abdominal pain, dyspepsia)
• Muscle aches or weakness (myalgia)
• Elevated liver enzymes (ALT, AST)

Rare

• Cholestatic hepatitis
• Pancreatitis (particularly in patients with very high triglycerides)
• Severe skin reactions (e.g., Stevens‑Johnson syndrome)

Serious

• Rhabdomyolysis, especially when combined with high‑dose statins or cytochrome P450 3A4 inhibitors (e.g., clarithromycin, itraconazole)
• Acute renal failure secondary to rhabdomyolysis or hypersensitivity
• Hepatic failure in patients with pre‑existing liver disease

Drug–Drug Interactions

• Statins – Co‑administration raises the risk of myopathy; consider dose reduction of the statin or choose a statin with lower interaction potential (e.g., pravastatin).
• Anticoagulants (warfarin) – Fenofibrate may potentiate anticoagulant effect; monitor INR more frequently.
• Cytochrome P450 3A4 inhibitors – Increase fenofibrate plasma concentrations, heightening toxicity risk.
• Bile‑acid sequestrants – May reduce fenofibrate absorption; separate dosing by at least 2 hours.

Patients should disclose all medications, herbal supplements, and over‑the‑counter products to their healthcare provider before initiating fenofibrate.

Practical Use: Dosing, Missed Dose, Overdose

• Standard dosing – For adults, the usual dose is 145 mg once daily (microsphere formulation) or 160 mg once daily (immediate‑release tablets). Dose adjustments are required for renal impairment (e.g., 54 mg daily for creatinine clearance 30–50 mL/min).
• Administration – Tablets should be taken with a low‑fat meal to enhance absorption; the microsphere formulation can be taken with or without food.
• Missed dose – If a dose is forgotten, take it as soon as remembered unless it is within 12 hours of the next scheduled dose. Do not double the dose to compensate.
• Overdose – Symptoms may include severe nausea, vomiting, abdominal pain, and dizziness. Contact emergency services or a poison control centre promptly. Management is supportive, including gastric decontamination if presentation is within one hour and monitoring of liver and renal function.

Precautions – Avoid excessive alcohol consumption, which can exacerbate hepatic toxicity. Patients with gallstones should be monitored closely, as fenofibrate can increase biliary cholesterol saturation.

Buying Fenofibrate from Our Online Pharmacy

Fenofibrate can be purchased from our online pharmacy in Hong Kong with a streamlined ordering process.

• Affordable pricing – We source the generic product near manufacturer cost, providing a lower price than most retail pharmacies.
• Verified quality – All supplies come from licensed overseas manufacturers that meet international Good Manufacturing Practice (GMP) standards.
• Guaranteed delivery – Discreet, reliable shipping options include 7‑day express service or approximately 3‑week regular airmail, with tracking provided for every order.
• Online‑only access – Our pharmacy broker service collaborates with overseas licensed pharmacies, enabling a private, privacy‑respecting channel for patients who have limited access to the medication locally or whose insurance does not cover it.

By choosing our online pharmacy, patients obtain a trustworthy, cost‑effective alternative for fenofibrate therapy while maintaining confidentiality.

FAQ

• Is fenofibrate available in both brand‑name and generic forms in Hong Kong?
  Yes. The medication is marketed under brand names such as Tricor and Lofibra, as well as generic versions produced by multiple manufacturers. Generic fenofibrate contains the identical active ingredient and is typically less expensive.

• What storage conditions are recommended for fenofibrate tablets?
  Store at room temperature (20 °C–25 °C) in a dry place, away from direct sunlight, heat, and moisture. Keep the container tightly closed and out of reach of children.

• Can fenofibrate be taken with a high‑fat meal?
  The immediate‑release formulation is best absorbed with a low‑fat meal, whereas the microsphere version may be taken with or without food. High‑fat meals can increase absorption but also raise the risk of gastrointestinal discomfort.

• How does fenofibrate differ from other fibrates such as gemfibrozil?
  Both activate PPAR‑α, but fenofibrate has a longer half‑life and a slightly stronger effect on HDL‑cholesterol. It also displays a lower incidence of drug–drug interactions with statins compared with gemfibrozil.

• Is routine liver function monitoring required while on fenofibrate?
  Baseline liver enzymes should be measured before therapy, and periodic monitoring (e.g., annually) is recommended, especially in patients with pre‑existing liver disease or those taking hepatotoxic concomitant drugs.

• Can fenofibrate be safely imported for personal use in Hong Kong?
  Personal import of up to a 30‑day supply for self‑use is permitted under Hong Kong customs regulations, provided the product is accompanied by a valid prescription and originates from a licensed overseas pharmacy.

• What are the signs of serious muscle toxicity that require immediate medical attention?
  Sudden muscle pain, weakness, dark‑colored urine, and elevated creatine kinase levels may indicate rhabdomyolysis. Prompt evaluation is essential to prevent renal complications.

• Does fenofibrate have any effect on blood glucose levels?
  Clinical data suggest a modest improvement in fasting glucose and insulin sensitivity in patients with type 2 diabetes, but fenofibrate is not a primary antidiabetic agent.

• Are there any special considerations for elderly patients taking fenofibrate?
  Older adults often have reduced renal function; dosage adjustments based on creatinine clearance are advisable. Monitoring for hepatic and muscle side effects is also important.

• What packaging does fenofibrate come in when ordered online?
  The medication is supplied in blister packs or sealed bottles containing 30 or 90 tablets, each labeled with the product name, strength, batch number, and expiry date to ensure traceability.

• Can fenofibrate be used during pregnancy or breastfeeding?
  Fenofibrate is classified as pregnancy category C (risk cannot be ruled out). It should be avoided unless the potential benefit justifies the risk. Excretion into breast milk is unknown; lactating women should consult a healthcare professional before use.

• How does the microsphere formulation improve tolerability?
  The microsphere (extended‑release) version releases fenofibrate gradually, reducing peak plasma concentrations and minimizing gastrointestinal irritation compared with immediate‑release tablets.

Glossary

PPAR‑α (Peroxisome proliferator‑activated receptor‑α)

A nuclear receptor that regulates genes involved in fatty‑acid oxidation and lipid metabolism; activation lowers triglyceride levels.

Hypertriglyceridaemia

A condition where fasting blood triglyceride concentrations exceed the normal range, increasing the risk of pancreatitis and atherosclerosis.

Myopathy

Muscle disease characterized by weakness, pain, or inflammation; can be drug‑induced, especially when fibrates are combined with statins.

Creatinine clearance

An estimate of kidney function based on serum creatinine; used to adjust drug dosing in renal impairment.

⚠️ Disclaimer

The information provided about Fenofibrate is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Fenofibrate for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.